期刊文献+

液质联用分析抗风湿类保健食品中非法添加的Janus激酶抑制药 被引量:1

Determination of the Illegally Added JAK Inhibitors in Anti-rheaumatic Dietary Supplements by LC-MS/MS
下载PDF
导出
摘要 目的:建立一种快速检测抗风湿类保健食品中5种Janus激酶(JAK)抑制药的分析方法。方法:采用液相色谱-串联四级杆质谱(LC-MS/MS),色谱柱:CAPCELL PAK C_(18)(3.0 mm×100 mm,3μm);流动相:0.1%甲酸乙腈(A)-0.1%乙酸溶液(B),梯度洗脱;流速:0.4 ml·min^(-1);柱温:35℃;电喷雾离子源(ESI),正离子采集模式,多反应检测模式(MRM)测定5种JAK抑制药,比较各通道对照品与样品的分子离子峰、碎片离子峰、色谱保留时间等信息确定非法添加的JAK抑制药种类。结果:5种JAK抑制药色谱分离良好,方法检出限为(LOD)0.02~0.21 ng·ml^(-1),定量限(LOD)为0.05~0.45 ng·ml^(-1),回收率在91.2%~102.9%。结论:该方法简单、准确,可用于保健食品中非法添加JAK抑制剂的检测。 Objective:To develop a rapid method for the determination of 5 JAK inhibitor compounds illegally added to the dietary supplements.Methods:The determination was performed by LC-MSMS,and the separation was achieved on a CAPCELL PAK C_(18)(3.0 mm×100 mm,3 μm)column in a gradient elution mode with 0.1% formic acid water and 0.1% formic acid acetonitrile as the mobile phase at a flow rate of 0.4 ml·min^(-1),the column temperature was 35℃,the mass spectrometry parameters were as follows:electrospray ionization(ESI),positive ion scan mode and a multiple reaction monitoring(MRM) mode were used to quantitatively determine the 5 JAK inhibitors,and the illegally added compounds were confirmed by comparing the molecular ion peak,product ion peak and retention time between the reference standards and the samples in different transitions.Results:The five JAK inhibitors were separated well,the method LODs were between 0.02 and 0.21 ng·ml^(-1),the LOQs were between 0.05 and 0.45 ng·ml^(-1),and the average recoveries were between 91.2% and 102.9%.Conclusion:The method is simple and accurate,and can be used for the determination of illegally added JAK inhibitors in dietary supplements.
作者 李慧玲 王嘉林 Li Huiling;Wang Jialin(Anyang Food and Drug Inspection and Testing Center,Henan Anyang 455000,China;Luoyang Institute for Food and Drug Control)
出处 《中国药师》 CAS 2022年第4期746-749,共4页 China Pharmacist
关键词 液相色谱-串联质谱 抗风湿 保健食品 Janus激酶抑制药 非法添加 LC-MS/MS Anti-rheaumatic Dietary supplements JAK inhibitors Illegally added
  • 相关文献

参考文献2

二级参考文献47

  • 1MANNING G, WHYTE DB, MARTINEZ R, et al. The protein kinase complement of the human genome [ J ]. Science, 2002, 298(5600) : 1912 - 1934. 被引量:1
  • 2SCHER JU. Monotherapy in rheumatoid arthritis[J]. Bull Hosp .It Dis, 2013, 71(3): 204-207. 被引量:1
  • 3FLEISCHMANN R. Don't forget traditional DMARDs[J]. Rheu- matology, 2011, 50(3):429-430. 被引量:1
  • 4BULA'OVIC M, HEIJSTEK MW, VERKAA1K M, et al. High Prevalence of Methotrexate Intolerance in Juvenile Idiopathic Ar- thritis: development and validation of a methotrexate intolerance severity score [ J]. Arthritis Rheum, 2011, 63 (7): 2007- 2013. 被引量:1
  • 5GAIES E, JEBABLI N, TRABELS1 S, et al. Methotrexate side effects : review article [ J ]. J Drug Metab Toxicol, 2012,3 ( 4 ) : 125 - 130. 被引量:1
  • 6HENNIGAN S, KAVANAUGH A. Interleukin-6 inhibitors in the treatment of rheumatoid arthritis[J]. Therapeut Clin Risk Manag, 2008,4(4) :767 -775. 被引量:1
  • 7MACFARLANE LA, TODD DJ. Kinase inhibitors: The next generation of therapies in the treatment of rheumatoid arthritis [J]. Int J Rheum Dis,2014,17(4): 359 -368. 被引量:1
  • 8COHEN S, FLEISCHMANN R. Kinase inhibitors: a new ap- proach to rheumatoid arthritis treatment[ J] Curr Opin Rheuma- tol,2010,22(3) :330 - 335. 被引量:1
  • 9ASTRAZENECA PLC. AstraZeneca announces top-line results from Phase III OSKIRA trials of FOSTAMATINIB and decision not to proceed with regulatory filings[ R/OL]. AstraZeneca Press [ 2013 - 06 - 04 ]. http://www, astrazeneea, corn/Media/Press- releases/Article/20130504-astrazeneca-announces-topline-results- ffom-phase-iii-o. 被引量:1
  • 10O'SULLIVAN LA, LIONGUE C, LEWIS RS, et al. Cytokine re- ceptor signaling through the Jak Stat pathway in disease[J]. Mol lmmunol,2007,44(10) :2497 -2506. 被引量:1

共引文献14

同被引文献13

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部